Gamal Mohamed El Maghraby (Gamal M ElMaghraby, Gamal M El Maghraby)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 16

Top Topics

Molecularly Imprinted

Atomic Force Microscopy

High Resolution

Pulmonary Arterial Hypertension

Top Venues

Drug development and industrial pharmacy

Scientific reports

AAPS PharmSciTech

International journal of nanomedicine

This page only lists publications with an associated author ORCID identifier.

Publications

Hend A Awad, Mohamed I Fetouh, Amal A Sultan, Gamal Mohamed El Maghraby
Combined eutexia and amorphization for simultaneous enhancement of dissolution rate of triamterene and hydrochlorothiazide: preparation of orodispersible tablets. Drug development and industrial pharmacy 50 (4) (2024)
Rania K Eid, Mona F Arafa, Gamal Mohamed El Maghraby
Water in nigella oil microemulsion for enhanced oral bioavailability of linagliptin. Drug delivery and translational research (2024)
Hend A Awad, Mohamed I Fetouh, Amal A Sultan, Gamal Mohamed El Maghraby
Combined eutexia and amorphization for simultaneous enhancement of dissolution rate of triamterene and hydrochlorothiazide: preparation of orodispersible tablets. Drug development and industrial pharmacy 50 (4) (2024)
Hend A Awad, Mohamed I Fetouh, Amal A Sultan, Gamal Mohamed El Maghraby
Combined eutexia and amorphization for simultaneous enhancement of dissolution rate of triamterene and hydrochlorothiazide: preparation of orodispersible tablets. Drug development and industrial pharmacy (2024)
Hend A Awad, Mohamed I Fetouh, Amal A Sultan, Gamal Mohamed El Maghraby
Combined eutexia and amorphization for simultaneous enhancement of dissolution rate of triamterene and hydrochlorothiazide: Preparation of orodispersible tablets. Drug development and industrial pharmacy (2024)
Rania Mohamed Sakr, Abdelaziz El Sayed Abdelaziz, Eman Ahmed Mazyed, Gamal Mohamed El Maghraby
Preparation of orodispersible tablets of bosentan using xylitol and menthol as dissolution enhancers. Scientific reports 14 (1) (2024)
Mohammed I Ghanem, Shimaa M Ashmawy, Gamal Mohamed El Maghraby
Intestinal Absorption Site-Guided Development and Evaluation of Oral Disintegrating Controlled Release Tablets of Mirabegron. AAPS PharmSciTech 25 (6) (2024)
Rania Mohamed Sakr, Abdelaziz El Sayed Abdelaziz, Eman Ahmed Mazyed, Gamal Mohamed El Maghraby
Preparation of orodispersible tablets of bosentan using xylitol and menthol as dissolution enhancers. Scientific reports 14 (1) (2024)
Rania Mohamed Sakr, Abdelaziz El Sayed Abdelaziz, Eman Ahmed Mazyed, Gamal Mohamed El Maghraby
Preparation of orodispersible tablets of bosentan using xylitol and menthol as dissolution enhancers. Scientific reports 14 (1) (2024)
Rania Mohamed Sakr, Abdelaziz El Sayed Abdelaziz, Eman Ahmed Mazyed, Gamal Mohamed El Maghraby
Preparation of orodispersible tablets of bosentan using xylitol and menthol as dissolution enhancers. Scientific reports 14 (1) (2024)
Ebtehal M Dorgham, Gamal Mohamed El Maghraby, Ebtessam A Essa, Mona F Arafa
Melting point depression for enhanced dissolution rate of eslicarbazepine acetate. Drug development and industrial pharmacy 48 (12) (2023)
Ebtehal M Dorgham, Gamal Mohamed El Maghraby, Ebtessam A Essa, Mona F Arafa
Melting point depression for enhanced dissolution rate of eslicarbazepine acetate. Drug development and industrial pharmacy (2023)
Ebtehal M Dorgham, Gamal Mohamed El Maghraby, Ebtessam A Essa, Mona F Arafa
Melting point depression for enhanced dissolution rate of eslicarbazepine acetate. Drug development and industrial pharmacy 48 (12) (2023)
Noha D Fayed, Ebtessam A Essa, Gamal Mohamed El Maghraby
Menthol augmented niosomes for enhanced intestinal absorption of lopinavir. Pharmaceutical development and technology 27 (9) (2022)
Amal A Sultan, Nourhan F El Nashar, Shimaa M Ashmawy, Gamal Mohamed El Maghraby
Cubosomes for Enhancing Intestinal Absorption of Fexofenadine Hydrochloride: In situ and in vivo Investigation. International journal of nanomedicine 17 (2022)
Ebtehal M Dorgham, Gamal Mohamed El Maghraby, Ebtessam A Essa, Mona F Arafa
Melting point depression for enhanced dissolution rate of eslicarbazepine acetate. Drug development and industrial pharmacy (2022)